Free Trial
NASDAQ:LQDA

Liquidia Technologies Q2 2025 Earnings Report

Liquidia Technologies logo
$18.72 +1.04 (+5.89%)
As of 01:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Liquidia Technologies EPS Results

Actual EPS
N/A
Consensus EPS
-$0.43
Beat/Miss
N/A
One Year Ago EPS
N/A

Liquidia Technologies Revenue Results

Actual Revenue
N/A
Expected Revenue
$3.90 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Liquidia Technologies Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Liquidia Technologies Earnings Headlines

Oppenheimer Keeps Their Sell Rating on Liquidia Technologies (LQDA)
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
See More Liquidia Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Liquidia Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Liquidia Technologies and other key companies, straight to your email.

About Liquidia Technologies

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

View Liquidia Technologies Profile

More Earnings Resources from MarketBeat